Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Core Viewpoint - A securities class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making false and misleading statements regarding its manufacturing processes and the prospects of its products, particularly briquilimab [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of individuals or entities that purchased Jasper securities between November 30, 2023, and July 3, 2025 [1]. - The complaint alleges that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results [2]. Group 2: Allegations Against the Company - The failure to ensure compliance with manufacturing regulations increased the risk of confounding study results, adversely affecting the regulatory and commercial prospects of Jasper's products [2]. - The allegations suggest that the company's business and financial prospects, as well as the clinical and commercial prospects of briquilimab, were overstated [2]. - As a result of these issues, the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 3: Investor Information - Investors who acquired shares of Jasper are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on November 18, 2025 [3].